Skip to content

Proactive Versus Reactive Strategy for Treatment of hypophosphatemia during Continuous Renal Replacement Therapy

Proactive Versus Reactive Strategy for Treatment of hypophosphatemia during Continuous Renal Replacement Therapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260216002
Enrollment
144
Registered
2026-02-16
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients receiving continuous renal replacement therapy hypophosphatemia, CRRT, phosphate-containing solution

Interventions

- Participants in the Proactive Strategy group will receive phosphate-containing solutions until CRRT discontinuation. - The type of solution depends on the anticoagulation protocol: Non-citrate anti
Experimental Other,Active Comparator Other
Proactive strategy,Reactive strategy

Sponsors

Peerapat Thanapongsatorn
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years. 2.Patients undergoing Continuous Renal Replacement Therapy (CRRT) with at least one of the following indications: 2.1 Persistent metabolic abnormalities (e.g., severe metabolic acidosis, hyperkalemia) refractory to intermittent hemodialysis. 2.2 Cerebral edema or risk of cerebral edema (e.g., acute liver failure, acute stroke, hypoxic-ischemic brain injury post-cardiac arrest). 2.3 Fluid overload refractory to medical therapy or intermittent hemodialysis, particularly fluid accumulation > 10% of baseline body weight. 2.4 Requirement for continuous control of fluid, acid-base, and electrolyte balance. 3. Patients requiring mechanical ventilation. 4. Serum phosphorus levels between 2.5 and 5.5 mg/dL within 48 hours of CRRT initiation.

Exclusion criteria

Exclusion criteria: 1.Moribund state by the treating physicians to have a low probability of survival within 24 hours. 2. Volunteers who have received a kidney transplant. 3. Pregnant volunteers.

Design outcomes

Primary

MeasureTime frame
Ventilator-free days at 28 days at 28 days after end of the intervention Duration of ventilator-free days

Secondary

MeasureTime frame
Hyperphosphatemia Within 28 days after intervention phosphorus more than 5.5 mg/dL,severe hypophosphatemia Within 28 days after intervention serum phosphorus less than 0.8 mg/dL,Total days on ventilator Discharge date days on ventilator,Hospital length of stay Discharge date Hospital length of stay,ICU length of stay Discharge date ICU length of stay,Hospital mortality Discharge date Incidence of hospital mortality,Incidence of tracheostomy Discharge date Incidence of tracheostomy,Trajectory of serum Phosphate levels During CRRT Serum phosphorus

Countries

Thailand

Contacts

Public ContactPeerapat Thanapongsatorn

Thammasat University Hospital

peerapat.manu@gmail.com029269999

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026